{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-23-000107","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2023-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.718792+00:00","generated_at":"2026-06-13T10:04:16.273450+00:00","sec_items":["1.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BeiGene terminates TIGIT inhibitor option pact with Novartis; regains full rights to ociperlimab","bullets":["Mutual termination effective July 10, 2023; BeiGene Switzerland regains global rights to develop, manufacture and commercialize ociperlimab.","Phase 3 AdvanTIG 302 trial of ociperlimab + tislelizumab for 1L NSCLC with high PD-L1 will continue enrollment.","Phase 3 AdvanTIG 301 trial in stage III unresectable NSCLC discontinued due to changing treatment paradigm.","Option agreement originally disclosed December 19, 2021; no financial terms of termination disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-23-000107","json":"https://secwatch.observer/filing/0001651308-23-000107.json","markdown":"https://secwatch.observer/filing/0001651308-23-000107.md","text":"https://secwatch.observer/filing/0001651308-23-000107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000107/0001651308-23-000107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000107/bgne-20230710.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:04:16.273450+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"335c3fc72932ae2d11e89f9cfb66d3fec763382c","claim":"BeOne Medicines Ltd. terminated Option, Collaboration and License Agreement with Novartis Pharma AG valued at Mutual termination of the Option Agreement, effective immediately. (effective 2023-07-10).","evidence_excerpt":"Item 1.02. Termination of a Material Definitive Agreement. As previously disclosed, on December 19, 2021, BeiGene Switzerland GmbH (“BeiGene Switzerland”), a wholly-owned indirect subsidiary of BeiGene, Ltd. (the “Company”), entered into an Option, Collaboration and License Agreement (the “Option Agreement”) with Novartis Pharma AG (“Novartis”), pursuant to which BeiGene Switzerland granted Novartis an exclusive time-based option to receive an exclusive license to develop, manufacture and commercialize the Company’s investigational TIGIT inhibitor ociperlimab in certain territories. On July 10, 2023, BeiGene Switzerland and Novartis entered into a Mutual Termination and Release Agreement (the “Termination Agreement”) to mutually terminate the Option Agreement, effective immediately.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000107/0001651308-23-000107-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Novartis Pharma AG"},{"label":"Value","value":"Mutual termination of the Option Agreement, effective immediately."},{"label":"Effective","value":"2023-07-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}